These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24858643)

  • 1. Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.
    Marcotullio S; Ammassari A; Andreoni M; Antinori A; Bonora S; d'Arminio Monforte A; Di Perri G; Galli M; Gervasoni C; Iardino R; Ippolito G; Lo Caputo S; Nozza S; Perno CF; Rizzardini G; Lazzarin A
    New Microbiol; 2014 Apr; 37(2):163-75. PubMed ID: 24858643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
    Naggie S; Hicks C
    J Antimicrob Chemother; 2010 Jun; 65(6):1094-9. PubMed ID: 20418273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
    Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Furrer H; Telenti A; Hirschel B; Vernazza PL; Bernasconi E; Rickenbach M; Perrin L; Ledergerber B; Günthard HF;
    Arch Intern Med; 2007 Sep; 167(16):1782-90. PubMed ID: 17846398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
    Gianotti N; Tambussi G; Boeri E; Lazzarin A
    J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
    De Luca A; Hamers RL; Schapiro JM
    J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The great salvage therapy drug juggle.
    Cadman J
    GMHC Treat Issues; 1998 Apr; 12(4):1-6. PubMed ID: 11365398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning of HIV-protease inhibitors in clinical practice.
    Andreoni M; Perno CF
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):10-8. PubMed ID: 22338543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M
    J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Giacomet V; Bernardi S; Esposito S; Rosso R; Giaquinto C; Badolato R; Guarino A; Maccabruni A; Masi M; Cellini M; Salvini F; Di Bari C; Dedoni M; Dodi I; de Martino M;
    Acta Paediatr; 2012 Jul; 101(7):e287-95. PubMed ID: 22452359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.